Comparison of high‐dose dual therapy with bismuth‐containing quadruple therapy in <i>Helicobacter pylori</i>‐infected treatment‐naive patients: An open‐label, multicenter, randomized controlled trial

Abstract

High-dose dual therapy for H. pylori eradication had similar efficacy and compliance, fewer adverse events, and lower costs than bismuth-containing quadruple therapy for treatment-naive patients.